Brought to you by 
Cara Therapeutics brings in $4.8mm from Series D round
21 May 2012
Executive Summary
Cara Therapeutics Inc. (pain and inflammation) has raised $4.8mm of a potential $15mm through its Series D round. The company sold equity, preferred shares, and other rights to 12 investors including new buyer Rho Ventures (lead) and returning backers Alta Biopharma, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Healthcare Private Equity, Mitsubishi, and MVM Life Science Partners. Proceeds will be used to continue development of Cara's lead candidate CR845, a peripherally restricted kappa opioid agonist in Phase II for post-operative pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cara Therapeutics brings in $4.8mm from Series D round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice